We want to know more about what these products are doing,” said Dr. Vinay Prasad in a recent FDA livestreamed presentation. The statement is made as there has been a significant policy shift in the U.

BMO Capital Markets pointed to FDA leadership, and CBER Director Vinay Prasad in particular, as potential factors in the ...

In a July 9 memo, the director of the FDA's Center for Biologics Evaluation and Research contended there was not enough ...

The FDA on Tuesday rejected a skin therapy from Replimune Group, suggesting a hardened stance on drug approvals under new agency officials ...

MAGA supporters such as far-right political activist Laura Loomer have dubbed his appointment "baffling" and a "betrayal of the voters who elected Trump".

Dr. Vinay Prasad, a prominent critic of the pharmaceutical industry and the Food and Drug Administration, has been named to oversee the agency’s program for vaccines and biotech drugs.

(CNN) — The US Food and Drug Administration has named Dr. Vinay Prasad, a hematologist oncologist, to lead its Center for Biologics Evaluation and Research, the division that oversees vaccines and ...

Dr. Vinay Prasad, a prominent critic of the pharmaceutical industry and the Food and Drug Administration, has been named to oversee the agency’s program for vaccines and biotech drugs.

FDA Commissioner Marty Makary selected Dr. Vinay Prasad, a prominent critic of COVID-19 boosters, to lead the Center for Biologics Evaluation and Research.

(CNN) — The US Food and Drug Administration has named Dr. Vinay Prasad, a hematologist oncologist, to lead its Center for Biologics Evaluation and Research, the division that oversees vaccines ...

Dr. Vinay Prasad, a prominent critic of the pharmaceutical industry and the Food and Drug Administration, has been named to oversee the agency’s program for vaccines and biotech drugs.

Dr. Vinay Prasad, a professor at the University of California San Francisco, became a harsh critic of the government’s response and its vaccine policies during the Covid-19 pandemic.